The ability of NM23 deficiency to confer metastatic potential in HGF-driven melanoma suggests the HGF+ × [m1m2]+/− strain may be a relevant experimental model for human melanomas that do not harbor BRAF mutations (20–40 %) and are unsuitable candidates for anti-BRAF therapies [33]. The gene discussed is BRAF; the disease is melanoma.